Christine Ring - 04 Nov 2024 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring
Issuer symbol
NRIX
Transactions as of
04 Nov 2024
Net transactions value
-$50,765
Form type
4
Filing time
04 Nov 2024, 17:48:03 UTC
Previous filing
01 Nov 2024
Next filing
02 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $31,485 +3,290 +12% $9.57 31,374 04 Nov 2024 Direct F1
transaction NRIX Common Stock Sale $82,250 -3,290 -10% $25.00 28,084 04 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -3,290 -3.3% $0.000000 96,389 04 Nov 2024 Common Stock 3,290 $9.57 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024.